🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Energy Sector SEC Filings — May 12, 2026

Batch of 16 filings dominated by neutral 13F-HR disclosures from institutions (e.g., United Super $5.3B AUM, Stokes $969M, Chesapeake $126M) showing stable Q1 2026 holdings heavily skewed to tech mega-caps like NVDA ($327M top at United Super), AAPL, AMZN despite Energy sector focus, signaling broad market conviction in AI/big tech over pure energy plays. Energy sector highlights include SLB's $2B senior notes issuance at 4.55-5.15% (positive capital access for services/growth), Exxon's defensive DEFA14As rebutting proxy opposition to Texas redomicile (mixed governance risks), and Dorchester Minerals' annual meeting tomorrow with investor presentation. Operational trends mixed: Ampco-Pittsburgh Q1 sales +3.9% YoY to $108.3M and backlog to $345.5M on $124M orders but net loss $0.9M vs profit $1.1M YoY, Adj EBITDA margin -70bps to 7.4%; Orchestra BioMed revenue -87% YoY to $110k with loss widening 10%; XOMA income -23% YoY but net income +89% to $4.5k via gains; AOXY revenues +2% YoY. Cash flow improvements prominent (Ampco OCF +$7M YoY to +$1.7M, XOMA +178% to $6.1k, AOXY +37%). No insider trading activity noted across filings; capital allocation favors debt raises (SLB) and pension funding (Ampco fully funded). Portfolio-level: 10/14 new 13Fs neutral with sole discretionary holdings, no put/call shifts; implications point to energy tactical plays amid institutional tech stability.

4 high priority 12 medium 16 total filings
· daily

US Material Events SEC 8-K Filings — May 12, 2026

Across 50 US SEC filings from May 12, 2026, dominant themes include widespread executive transitions (24 cases, ~48% orderly retirements/appointments signaling continuity), robust annual meeting approvals (17 filings, avg 90%+ support for directors/equity plans/auditors), aggressive financing (18 cases: debt refinancings, equity raises, facilities with lower rates/costs), and M&A/JV activity (12 deals, total ~$2.5B+ value). Period-over-period trends show strong revenue acceleration in industrials/energy/semiconductors (e.g., SOLV +66% YoY Q1 rev to $677M, Arteris +39% YoY to $22.9M, Nextpower +20% FY26 to $3.56B) but mixed margins (improvements in SOLV gross +310bps to 17.6%, compressions in OptimizeRx amid macro pressures). Guidance upgrades in 7 firms (e.g., SOLV EBITDA $435-455M, Collegium rev $865-895M) contrast isolated downgrades/dilution risks; biopharma mixed with trial misses offset by partnerships (Arvinas $85M upfront). Portfolio-level: Semis/tech resilient (positive sentiment 80%), financials bolstering liquidity, health sector catalyst-rich but volatile; implies bullish rotation to growth industrials, caution on leadership-vacant energy.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 12, 2026

Across 50 SEC filings from Dow Jones 30-related streams, institutional 13F-HR reports (32/50) reveal overwhelming conviction in US tech giants (Apple, Microsoft, NVIDIA, Amazon topping nearly every portfolio, with aggregate values exceeding trillions), signaling bullish portfolio positioning amid ETF dominance for broad market exposure. Operational filings highlight robust LNG sector growth (Venture Global revenue +59% YoY to $4.6B, EBITDA guidance raised to $8.2-8.5B), accretive M&A (Global Net Lease acquiring Modiv for $535M, +4% AFFO accretive, Q3'26 close), and mixed small/mid-cap results (e.g., Optex revenue -10% YoY but margins +390 bps to 35.2%, FY guidance raised). Period trends show revenue growth in energy (avg +59% YoY) contrasting margin improvements in industrials/manufacturing (+390 bps) but declines in consumer/small caps (e.g., VenHub -86% YoY). Capital allocation favors dividends (Venture Global $0.02/share, Sound Financial +11% YoY to $0.21/share) and debt raises (Bain Capital $350M notes). Forward catalysts include Investor Days (S&P Global Mobility May 12, 2026), merger approvals (Volato/M2i), and court hearings (Honest Co. July 13, 2026), with neutral sentiment dominating 13Fs but positive M&A/earnings outliers driving actionable alpha in energy/REITs.

9 high priority 41 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 12, 2026

The May 12, 2026, SEC filings reveal a deluge of 13F-HR reports (over 30) from global institutions, showcasing overwhelming conviction in US tech giants like NVIDIA, Apple, Amazon, and semiconductors, with portfolio concentrations up to 43% in single names like AAPL, signaling sustained bullishness amid AI hype. Earnings and operational 8-Ks present mixed pictures: aerospace/defense names like Ducommun posted record revenue (+9% YoY) and margin expansion (+70 bps), while electronics firms like Qnity saw sales surge (+18% YoY) and raised FY guidance despite GAAP EPS drops. Capital markets activity thrives with IREN's $2.6B convertible notes pricing (positive) and eBay's rejection of GameStop's $20B bid, affirming standalone strength. Risks emerge in niche areas: BETA Technologies' losses widened dramatically (net loss to $122M from $78M YoY), Next Bridge Hydrocarbons reported revenue declines (-11% YoY) with zero reserves, and Maison Solutions faces Nasdaq delisting risk for missing annual meeting. Forward guidance leans optimistic in select industrials (e.g., Optex FY revenue up to $45M), but consumer segments weaken (Green Dot GDV -8% YoY). Portfolio-level trends highlight margin resilience in defense (+70 bps avg across Ducommun/Optex) versus compression elsewhere, positioning aerospace as a relative outperformer amid industrial softness.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 12, 2026

The May 12, 2026, filings for S&P 500 Consumer Discretionary reveal heavy institutional conviction via 40+ 13F-HRs, with Amazon.com as a top holding across 12 portfolios (e.g., 17.9%/$134M at GCQ Funds, $999M at Mitsubishi UFJ, $306M at United Super), alongside Uber (14%/$105M at GCQ) and exposure to eBay peers, signaling sustained allocation to e-commerce and ride-sharing amid neutral sentiment. Operational highlights include Aramark's robust Q2 FY2026 results (+15% YoY revenue to $4.9B, +12% organic, +40% adj EPS to $0.49, +116% FCF), eBay's rejection of GameStop's non-binding $20B debt-financed bid citing $80B 2025 GMV standalone strength, and mixed hospitality metrics like Ashford Hospitality's hotel sale improving pro forma net loss -4% YoY and SmartStop Self Storage's occupancy dip -70bps YoY to 92.3%. Period trends show growth divergence: 15-115% YoY revenue surges in services/infra (Aramark, JFB Construction, Cardinal Infrastructure) vs declines in volumes/occupancy (-11% rev at Next Bridge, rates down at SmartStop). Forward guidance is optimistic (e.g., Figure's Q2 vol $3.8-4.1B, Cardinal FY rev raised to $675-685M, Aramark leverage <3x FYE), with capital returns via Aramark's $25M buyback/$55M debt paydown/$0.12 dividend and Sound Financial's dividend hike to $0.21/share. Executive risks emerge (HF Sinclair CEO separation $4.7M severance, CFO leave), but no broad insider selling; overall, bullish flows favor selective e-comm/services overweight with hospitality watch.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 12, 2026

Across 50 filings dominated by Q1 2026 13F-HR disclosures, institutional investors maintain heavy overweight in mega-cap tech (AAPL top holding in 20+ managers, NVDA/LLY in select like Matthew 25's $25M LLY stake), signaling broad conviction amid limited S&P 500 Healthcare direct exposure beyond ETF proxies. Biotech filings (ProMIS, CalciMedica, Achieve, Sagimet, Unicycive, Harvard Bio, Pacira) reveal YoY net loss narrowing or swings to profit (e.g., Sagimet -41%, Achieve -20.6%, CalciMedica +$10M swing) driven by R&D cuts (-54% Sagimet, -17% CalciMedica), offset by $700M+ in fresh financings extending runways to 2027-2028. Revenue trends mixed: strong growth in sensors (VPG +17.6% YoY) vs declines in life sci tools (HBIO -4.7% YoY), with gross margins improving (HBIO +300bps to 59%). Forward catalysts cluster in H2 2026 (FDA feedbacks, trial readouts), while Pacira's proxy fight highlights activist risks. Non-health financials/REITs show deposit/asset growth (CB Financial +2.7% deposits QoQ) but expense pressures (New Mountain +27% YoY). Overall, actionable alpha in biotech pipelines undervalued vs sector, with institutional tech tilt implying healthcare laggard status.

11 high priority 39 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 12, 2026

Across 12 DEF 14A filings dated May 12, 2026, a dominant theme is clustered June 2026 shareholder meetings (10/12 between June 2-25) for director elections (11/12), auditor ratifications (9/12), say-on-pay votes (4/12), and advisory agreement approvals amid control changes or M&A (5/12 funds/ETFs). Period-over-period trends reveal stark contrasts: NVIDIA's explosive FY2026 revenue +65% YoY to $215.9B and EPS +67% to $4.90 outpace peers, while CarMax EPS plunged -47.7% YoY to $1.68 amid sales declines and impairments, Apogee sales edged +3% YoY but op margin contracted -270 bps to 6.0%, and funds show no financial declines but advisor disruptions. Mixed sentiment prevails (4/12 mixed), with high materiality in growth outliers (NVIDIA, CarMax 9/10) and fund transitions (MFS, Tavia 9/10). No insider trading or capital allocation shifts noted across filings, but director ownership at Dyadic (20.9%) signals alignment. Market implications include governance catalysts for volatility, potential continuity post-approvals boosting stability in funds/tech, and relative outperformance opportunities in high-growth names like NVDA versus cyclical decliners like KMX/APOG. Portfolio-level pattern: Margin compression in 3/4 detailed financials (avg -150 bps) despite uneven revenue growth, highlighting cost pressures amid transitions.

12 high priority 12 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 12, 2026

Three S-1 filings on May 12, 2026, highlight an active IPO pipeline with a SPAC (Tidewise), a distressed follow-on (Sunshine Biopharma), and a pre-IPO tech play (Amesite), focusing on healthcare/biotech/AI themes amid small-cap volatility. Amesite stands out with a 17.9% YoY net loss improvement to $3.617M in FY2025 (ended June 30, 2025) versus $4.403M in FY2024, signaling operational progress despite going concern doubts. Sunshine eyes $5M net proceeds from 5.825M units at $1.03 to boost pro forma cash 55% to $14.16M from $9.12M (Dec 31, 2025), but faces Nasdaq delisting risk with bid price flirting below $1.00. Tidewise's SPAC IPO at $10/unit details extensive dilution/redemption scenarios (up to 100%) with pro forma as of Oct 31, 2025, typical for blank-checks. Portfolio-level pattern: Mixed sentiment dominates (2/3 filings), with loss narrowing in Amesite as sole positive period trend, but pervasive risks like dilution, delisting, and cash burn underscore caution for IPO investors targeting turnarounds. No insider transactions noted, but concentrated ownership in Sunshine (Dr. Slilaty 100% Series B Pref votes) flags control dynamics. Implications: Watch for quick catalysts like Nasdaq decisions and financing closes in volatile small-cap healthcare/AI space.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — May 12, 2026

Across 50 filings in the 'Global High Priority Market Events' stream (US SEC and Indian exchanges, dated May 12, 2026), dominant themes include multiple corporate insolvencies and restructurings in Indian firms (e.g., Morarjee Textiles resolved, Arshiya with ₹67B claims), positive buyback announcements (Onward Technologies ₹18Cr, Garware ₹110Cr), and mixed Q1 2026 results with revenue growth averaging +35% YoY in outperformers like Rocket Companies (+167%) and SOLV Energy (+66%) but declines in consumer-facing names like Sleep Number (-19%). Period-over-period trends show 18/25 10-Qs with YoY revenue growth (avg +44% in positives), but margin compression in 12 cases (avg -150bps in mixed sentiment firms); capital allocation leans bullish with buybacks and dividends up YoY (e.g., Sound Financial +11% dividend). Critical developments: NCLT resolutions/takeovers (AVI open offer at ₹33/share), SPAC amendments, and raised guidance (SOLV EBITDA to $435-455M). Portfolio implications: Favor buyback plays and strong Q1 industrials amid insolvency risks in India; sector rotation toward semis/energy with hedges on consumer weakness.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 12, 2026

Across 50 Q1 2026 10-Q filings, mixed sentiment prevails in 44/50 cases, reflecting revenue volatility with 18 companies posting YoY growth (avg +35%, led by Rocket Companies +167% and Venture Global +59%) but 12 showing sharp declines (avg -45%, worst VenHub -86% and Longduoduo -76%). Net losses narrowed in 22 biotechs/pharmas (avg improvement 25%) via cost cuts, though cash burn persists; financials/banks saw NII growth in 5/8 (avg +20%) amid deposit/loan expansion. Balance sheets strengthened via equity raises in 15 firms (total ~$300M+ proceeds), but 10 reported cash declines >20% QoQ signaling liquidity strains. Capital allocation favors dividends (e.g., Sound Financial +11% payout) over buybacks, with no major M&A but ongoing projects like Venture Global's LNG. Portfolio trend: Margin resilience in growth names (avg +150bps gross margins) vs compression in decliners (-200bps avg), implying rotation to outperformers like Ducommun (+216% op income) amid sector dispersion.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 12, 2026

Three small-cap companies—Maison Solutions Inc., Beauty Health Co (SKIN), and BIO-Key International Inc (BKYI)—disclosed Nasdaq listing non-compliance notices in 8-K filings dated around May 6-12, 2026, signaling acute regulatory distress in the USA Trading Suspensions stream. Overarching themes include governance failures (annual meeting), reporting delays (late 10-K), and market price deficiencies (bid < $1), with all exhibiting negative sentiment and high materiality (9-10/10). No enriched period-over-period financial trends (YoY/QoQ revenue, margins) were detailed, but late filings and low bids imply operational deterioration and potential QoQ bid price declines exceeding 10 consecutive days for BKYI. Critical developments: imminent trading suspension for BKYI on May 13, 2026, with delisting to OTC, while others seek compliance plans; portfolio-level pattern shows 3/3 firms at delisting risk, eroding liquidity and shareholder value. Market implications: heightened volatility, short opportunities pre-suspension, and avoidance for long portfolios amid absent positive insider activity or capital returns data.

3 high priority 3 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 12, 2026

Across 36 filings in the USA Corporate Distress & Bankruptcy stream, key themes include Nasdaq listing non-compliance and imminent delistings in small caps (4/36 filings: Maison Solutions, Beauty Health, BIO-Key, with suspensions starting May 13, 2026), heavy reliance on dilutive equity/debt conversions and warrant issuances (6/36: Functional Brands, Securetech, Firefly, Perfect Moment, XCF Global), and ongoing debt forbearances signaling liquidity strains (Vivakor with $11.9M outstanding). Counterbalancing positives dominate larger caps with debt refinancings at lower rates (e.g., Sezzle -290bps spread, Procaccianti to 6.50%, Cinemark -0.25%, DHI extension to 2029), asset sales for non-dilutive cash (MacroGenics $122.5M), and M&A/debt-to-equity swaps (Diversified $1.175B acquisition, NSTS $73.7M buyout). Period-over-period trends limited but notable: OptimizeRx Q1 rev -10% YoY to $19.8M but adj EBITDA +120% to $3.3M, cash -14% QoQ to $20.2M; American Woodmark plant closure for $7.5M annual savings but $36-40M charges. No outright bankruptcies, but 11/36 exhibit clear distress signals vs 15 positive financings, indicating micro-cap vulnerability amid proactive deleveraging in mid/large caps. Forward catalysts cluster in Q2-Q3 2026 (compliance plans by late June, deal closes Q3), with portfolio-level margin trends unavailable but dilution risks elevated in 20% of filings.

36 high priority 36 total filings
· daily

US Executive Officer Management Changes SEC — May 12, 2026

Across 50 filings in the USA Executive & Director Changes stream (43 new), the dominant theme is routine annual shareholder meetings (20+ companies) approving directors, equity incentive plans (share increases averaging 4-6M shares), say-on-pay, and auditors with strong majorities, signaling stable governance amid minor oppositions (e.g., 20% against Piedmont's plan). Executive transitions dominate (25+ cases), mostly neutral/positive retirements/appointments (e.g., new COOs/CFOs/CEOs at Standard Motor, Laser Photonics, Eagle Bancorp) with seamless handovers, though negative separations (HF Sinclair CEO/CFO) and distress (Bitcoin Depot) stand out. Period trends show robust revenue growth in growth sectors (SOLV +66% YoY Q1 rev/$93M EBITDA +174%; Arteris +39% YoY; Nextpower FY26 +20% to $3.56B; TransAct +10% YoY) but widening losses (C3.ai FY26 op loss $(217.8)M vs $(88.1)M; Bitcoin -49% YoY rev). Capital allocation favors repurchases (Progressive 25M shares, TransAct $3M) and dividends (Progressive $0.10/share July 10), while M&A (SOLV $45M acquisition) and financings (Achieve $354M) support growth. Forward-looking catalysts include FDA dates (Achieve June 20), retirements (Arteris CFO Aug 31), and guidance raises (SOLV EBITDA $435-455M FY26), implying portfolio-level stability but sector-specific alpha in tech/energy transitions.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 12, 2026

Across 50 SEC filings on USA Board Room Changes from May 12, 2026, dominant themes include orderly executive transitions (12 CEO/CFO changes, mostly retirements/appointments with successors), annual shareholder meetings (20+ with director elections and equity plan approvals, averaging 90%+ support but 20% opposition on share increases), and board expansions with industry veterans (e.g., ex-TI, Caterpillar execs). Period-over-period trends show revenue acceleration in 7 reporters (avg +37% YoY: SOLV +66%, Arteris +39%, Nextpower +20%), but mixed profitability (SOLV EBITDA +174%, yet net losses widened in HF Sinclair, Bitcoin Depot -49% YoY rev). Guidance raised in SOLV ($435-455M EBITDA), Arteris ($91-95M rev), TransAct ($1-1.75M EBITDA), signaling growth conviction amid transitions. Capital allocation favors buybacks (TransAct $3M, Progressive 25M shares) and dividends (Progressive $0.10/share). Portfolio-level patterns: Financials/healthcare see high turnover (8 changes), tech/energy mixed financials with positive board sentiment (avg materiality 7/10). Implications: Bullish stability in most changes boosts confidence; monitor financial reporters for Q2 catalysts amid 5 negative departures.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 12, 2026

The 12 filings reveal a surge in US M&A and divestiture activity, with 7/12 involving asset sales, acquisitions, or JVs totaling over $5B in value, including Plains' $3.3B Canadian NGL divestiture and Collegium's $650M AZSTARYS buyout, signaling portfolio optimization and strategic refocusing amid mixed economic signals. Period-over-period trends show revenue declines in divestitures (e.g., Ashford -0.6% pro forma YoY to $1.1B) offset by loss improvements (Ashford net loss -4% to $181M, Mereo Q1 loss -48% YoY to $6.7M), while guidance upgrades (Collegium +8% revenue to $865-895M) highlight accretive deals. SPACs dominate extensions (4/5 filings), buying time for deals with neutral-to-positive sentiment. Energy midstream firms like Plains target 3.25-3.75x leverage post-sale for durable FCF, contrasting pharma's mixed clinical outcomes (Mereo Phase 3 misses primary but hits secondary endpoints). Overall, bullish on deleveraging and growth via M&A, but watch SPAC liquidity risks and clinical/regulatory hurdles; portfolio-level theme is crude oil focus and ADHD pharma expansion.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 12, 2026

Overnight SEC filings for May 11-12, 2026, are dominated by 37 13F-HR reports revealing strong institutional conviction in mega-cap tech (Apple, NVIDIA, Amazon topping 20+ portfolios, avg 20-40% allocation), signaling sustained bullishness on AI/semiconductors amid no reported changes from Q1 2026. Earnings releases show mixed Q1 2026 results: 5/7 reporting companies achieved revenue growth averaging +11% YoY (Ducommun +9%, Qnity +18%, Green Dot +17%), but margins varied (+70bps Ducommun to compressions elsewhere) and losses widened in high-growth names like BETA (+5.6% rev but -56% net income YoY). Guidance trends positive with raises (Qnity FY sales $5.225-5.375B, Optex FY rev $43-45M up from $41.3M), offset by widened loss outlooks (BETA Adj EBITDA -$355-445M). Capital raises prominent (IREN $2.6B notes due 2033, UGI €300M notes), exec transitions neutral-to-positive (Diodes new Chair, Astrana CMO resignation), and risks in compliance (Maison Nasdaq violation). Sector themes highlight aero/defense resilience, electronics outperformance, and heavy foreign investor tech bets; actionable now: buy electronic/aero dips pre-catalysts, monitor tech overweight for rotation risks.

6 high priority 44 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 11, 2026

The May 11, 2026 period recorded 1 Other approval in the biotech small-cap stream: ZHEJIANG NOVUS's VORICONAZOLE under FALLBACK type, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other. This single event carries a neutral signal (strength 5/10, materiality 5/10) with no dominant therapeutic area theme evident. The highest-conviction signal is ZHEJIANG NOVUS's VORICONAZOLE approval, a biosimilar entry with fully NOT_DISCLOSED commercial metrics including peak sales, exclusivity, and pricing power. Balanced upside exists for the entrant via potential market access, offset by execution risks in a mature antifungal space. Key risk/watch item is ZHEJIANG NOVUS launch dynamics and competitive positioning given limited disclosed details.

1 total filings
· daily

New Drug Approvals (Original) — May 11, 2026

The May 11, 2026 period saw 1 FDA approval categorized as Other (0 NMEs, 0 biosimilars, 0 label expansions), consisting solely of ZHEJIANG NOVUS's VORICONAZOLE biosimilar approval with a neutral signal (strength 5/10, materiality 5/10). No dominant therapeutic area theme emerges from this single approval. The highest-conviction signal is the neutral commercial implication for ZHEJIANG NOVUS's entry into the VORICONAZOLE market, representing a fallback approval with no disclosed peak sales, exclusivity, or pricing data. This dual-edged event is bullish for the new entrant ZHEJIANG NOVUS but bearish for the VORICONAZOLE originator due to potential revenue erosion. Key risk/watch item is competitive pressure on the originator's market position post-launch.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 11, 2026

Across 38 diverse SEC filings dominated by institutional 13F-HR disclosures, a clear portfolio-level pattern emerges of unwavering conviction in S&P 500 Technology mega-caps, with 12+ institutions reporting unchanged top holdings in Apple ($100M+ positions across NLB, MUFG EMEA, Elo, Nomura), Broadcom ($70M+ in NLB, $308M MUFG EMEA), Alphabet, Amazon, and Nvidia amid Q1 2026 portfolio stability. Period-over-period trends show mixed revenue performance outside tech: declines averaging -10% YoY in media (Townsquare -1.9%), semis (Sequans -29%), and logistics nine-month (Radiant -1.4%), offset by pockets of resilience like digital ad growth (+6.9% Townsquare) and hotel rev surges (+35% Portsmouth). Capital allocation favors dividends (Townsquare $0.20, Esquire $0.20 up from $0.175, Mueller $0.35), buybacks (Radiant $3.5M), while biotechs face cash burn (MoonLake -72% net loss YoY, runway to 2027). Forward-looking catalysts cluster in biotech (MoonLake BLA Sep 2026) and media guidance reaffirmations, but liquidation (Elme assets -72% QoQ) and going concern doubts (Planet Green) signal distress in non-core holdings. Implications: Bullish tech overweight via institutions supports sector rotation; selective opportunities in guided growth names amid broader small-cap weakness.

12 high priority 26 medium 38 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 11, 2026

Across 37 filings from NASDAQ-100 related entities on May 11, 2026, dominant themes include positive biotech catalysts (e.g., MoonLake, Intellia advancing BLAs), institutional stability with unchanged heavy tech allocations in 13Fs (Apple, Alphabet topping multiple portfolios), mixed quarterly results showing loss narrowing in small caps like Radiant Logistics (+88% net income YoY) and biotechs despite revenue dips, and ongoing liquidations/debt issuances signaling capital maneuvers. Period-over-period trends reveal 6/12 operational filings with YoY net loss improvements (avg +45% narrowing, e.g., Intellia -16%, Radiant +88%), but revenue stagnation/declines in logistics (Radiant flat) and semis/comms (Sequans -29%). Capital allocation leans toward buybacks (Radiant $3.5M), dividends (Mueller $0.35/share), and debt raises (Alphabet €9B, Booking €1.9B) for growth funding. Biotech forward-looking dominates with 4 BLA/PDUFA catalysts H2 2026-H1 2027, while Elme's liquidation eyes mid-2026 completion with $431M proceeds. Portfolio implications favor biotech alpha amid tech overweight stability, but flag cash burns and liquidation risks.

14 high priority 23 medium 37 total filings